{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:13Z","timestamp":1793115313771,"version":"4.5.0"},"reference-count":128,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Aberrant alternative splicing is increasingly recognized as a fundamental driver of cancer initiation and progression. The splicing factor 3b (SF3b) complex, an essential component of the U2 small nuclear ribonucleoprotein, plays a pivotal role in branch point sequence recognition and in coordinating spliceosome assembly and activation. Recent advances in cryogenic electron microscopy have revealed the structural plasticity of the SF3b complex, highlighting its dynamic transition between open and closed conformations that stabilize pre-mRNA substrates during the splicing cycle. Genetic and functional perturbations of SF3b, particularly recurrent mutations in its core subunit SF3B1, are frequently observed in human malignancies, most prominently in myelodysplastic syndromes and chronic lymphocytic leukemia. These alterations reshape splice-site selection, generate aberrant transcript isoforms, and reprogram cancer-relevant signaling pathways. In this review, we integrate current knowledge of the molecular architecture and regulatory dynamics of the SF3b complex with its emerging roles in cancer-associated splicing programs. We discuss the consequences of SF3b mutations and nonmutational dysregulation on transcriptome remodeling, genome stability, and tumor cell fitness, as well as the contribution of posttranslational modifications of SF3b components to splicing control. Furthermore, we critically evaluate recent progress in targeting the SF3b complex, focusing on the structural basis of SF3b inhibitors, insights gained from preclinical studies, and lessons learned from early-phase clinical trials. Collectively, this review positions the SF3b complex as a disease-modifying hub at the intersection of RNA splicing and cancer biology and highlights the opportunities and challenges associated with therapeutically targeting spliceosome components in oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020106","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:02:46Z","timestamp":1786744966000},"page":"6915-6931","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities"],"prefix":"10.1182","volume":"10","author":[{"given":"Shuling","family":"Li","sequence":"first","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Shang","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"4The First Clinical College of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yang","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"4The First Clinical College of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Huang","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5246-0794","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Xie","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-4028","authenticated-orcid":false,"given":"Zigang","family":"Dong","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-643X","authenticated-orcid":false,"given":"Yanan","family":"Jiang","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-5625","authenticated-orcid":false,"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[{"name":"1China-US (Henan) Hormel Cancer Institute, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"2State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China"},{"name":"3Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"19","key":"2026102711130452600_bib1","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.molcel.2024.07.019","article-title":"Molecular impact of mutations in RNA splicing factors in cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Mol Cell"},{"issue":"1","key":"2026102711130452600_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-024-01734-2","article-title":"Alternative splicing and related RNA binding proteins in human health and disease","volume":"9","author":"Tao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2026102711130452600_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/gutjnl-2024-333127","article-title":"Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges","volume":"74","author":"Jia","year":"2025","journal-title":"Gut"},{"issue":"6302","key":"2026102711130452600_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.aag0291","article-title":"Structure of a yeast activated spliceosome at 3.5 \u00c5 resolution","volume":"353","author":"Yan","year":"2016","journal-title":"Science"},{"key":"2026102711130452600_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-biochem-091719-064225","article-title":"RNA splicing by the Spliceosome","volume":"89","author":"Wilkinson","year":"2020","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"2026102711130452600_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1261\/rna.079273.122","article-title":"Spliceosome assembly and regulation: insights from analysis of highly reduced spliceosomes","volume":"29","author":"Black","year":"2023","journal-title":"RNA"},{"issue":"15","key":"2026102711130452600_bib7","doi-asserted-by":"crossref","first-page":"gkaf759","DOI":"10.1093\/nar\/gkaf759","article-title":"A common structural mechanism for RNA recognition by the SF3B complex in mRNA splicing and export","volume":"53","author":"Zhang","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"5621","key":"2026102711130452600_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1126\/science.1084155","article-title":"Molecular architecture of the multiprotein splicing factor SF3b","volume":"300","author":"Golas","year":"2003","journal-title":"Science"},{"issue":"5","key":"2026102711130452600_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1101\/gad.2014311","article-title":"Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A","volume":"25","author":"Corrionero","year":"2011","journal-title":"Genes Dev"},{"issue":"4","key":"2026102711130452600_bib10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.celrep.2015.03.048","article-title":"SF3B1 association with chromatin determines splicing outcomes","volume":"11","author":"Kfir","year":"2015","journal-title":"Cell Rep"},{"key":"2026102711130452600_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ebiom.2018.12.025","article-title":"Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma","volume":"39","author":"Sciarrillo","year":"2019","journal-title":"eBioMedicine"},{"issue":"11","key":"2026102711130452600_bib12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jclinpath-2019-205895","article-title":"Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia","volume":"72","author":"Foy","year":"2019","journal-title":"J Clin Pathol"},{"issue":"1","key":"2026102711130452600_bib13","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1038\/s41467-024-51380-z","article-title":"In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications","volume":"15","author":"Anglada-Girotto","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"2026102711130452600_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol Ther"},{"key":"2026102711130452600_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.copbio.2019.01.003","article-title":"Therapeutic approaches to treat human spliceosomal diseases","volume":"60","author":"DeNicola","year":"2019","journal-title":"Curr Opin Biotechnol"},{"issue":"18","key":"2026102711130452600_bib16","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1007\/s00018-020-03493-z","article-title":"The SF3b complex: splicing and beyond","volume":"77","author":"Sun","year":"2020","journal-title":"Cell Mol Life Sci"},{"issue":"27","key":"2026102711130452600_bib17","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/acs.jpclett.3c01402","article-title":"Cancer-related mutations alter RNA-driven functional cross-talk underlying premature-messenger RNA recognition by splicing factor SF3b","volume":"14","author":"Spinello","year":"2023","journal-title":"J Phys Chem Lett"},{"issue":"1","key":"2026102711130452600_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41420-022-01120-3","article-title":"The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov"},{"issue":"1","key":"2026102711130452600_bib19","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1038\/s41467-023-41297-4","article-title":"KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics","volume":"14","author":"Mouti","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"2026102711130452600_bib20","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1038\/s41467-025-62003-6","article-title":"Determination of trunk neural crest cell fate and susceptibility to splicing perturbation by the DLC1-SF3B1-PHF5A splicing complex","volume":"16","author":"Zheng","year":"2025","journal-title":"Nat Commun"},{"key":"2026102711130452600_bib21","doi-asserted-by":"crossref","first-page":"747344","DOI":"10.3389\/fgene.2021.747344","article-title":"Sequence divergence and functional specializations of the ancient spliceosomal SF3b: implications in flexibility and adaptations of the multi-protein complex","volume":"12","author":"Yazhini","year":"2021","journal-title":"Front Genet"},{"issue":"2","key":"2026102711130452600_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","article-title":"Molecular architecture of SF3b and structural consequences of its cancer-related mutations","volume":"64","author":"Cretu","year":"2016","journal-title":"Mol Cell"},{"issue":"1","key":"2026102711130452600_bib23","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1038\/s41467-024-50785-0","article-title":"Molecular basis for the activation of human spliceosome","volume":"15","author":"Zhan","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"2026102711130452600_bib24","doi-asserted-by":"crossref","first-page":"e0229315","DOI":"10.1371\/journal.pone.0229315","article-title":"Impact of cancer-associated mutations in Hsh155\/SF3b1 HEAT repeats 9-12 on pre-mRNA splicing in Saccharomyces cerevisiae","volume":"15","author":"Kaur","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"2026102711130452600_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1261\/rna.2224411","article-title":"Structural model of the p14\/SF3b155 \u00b7 branch duplex complex","volume":"17","author":"Schellenberg","year":"2011","journal-title":"Rna"},{"issue":"3","key":"2026102711130452600_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/cb100248e","article-title":"Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product","volume":"6","author":"Hasegawa","year":"2011","journal-title":"ACS Chem Biol"},{"issue":"3","key":"2026102711130452600_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1021\/cb400695j","article-title":"Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives","volume":"9","author":"Lagisetti","year":"2014","journal-title":"ACS Chem Biol"},{"issue":"2","key":"2026102711130452600_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/pro.3080","article-title":"Solution structure of the first RNA recognition motif domain of human spliceosomal protein SF3b49 and its mode of interaction with a SF3b145 fragment","volume":"26","author":"Kuwasako","year":"2017","journal-title":"Protein Sci"},{"issue":"3","key":"2026102711130452600_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1261\/rna.080368.124","article-title":"SF3B1: from core splicing factor to oncogenic driver","volume":"31","author":"Bak-Gordon","year":"2025","journal-title":"Rna"},{"issue":"2","key":"2026102711130452600_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2026102711130452600_bib31","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"2026102711130452600_bib32","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.3390\/cancers14194927","article-title":"SF3B1 mutations in hematological malignancies","volume":"14","author":"Cilloni","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2026102711130452600_bib33","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov"},{"key":"2026102711130452600_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2026102711130452600_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/path.4483","article-title":"SF3B1 mutations constitute a novel therapeutic target in breast cancer","volume":"235","author":"Maguire","year":"2015","journal-title":"J Pathol"},{"issue":"4","key":"2026102711130452600_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CMR.0000000000000071","article-title":"Rare SF3B1 R625 mutations in cutaneous melanoma","volume":"24","author":"Kong","year":"2014","journal-title":"Melanoma Res"},{"issue":"12","key":"2026102711130452600_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"70","key":"2026102711130452600_bib38","doi-asserted-by":"crossref","first-page":"115018","DOI":"10.18632\/oncotarget.22983","article-title":"SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"2026102711130452600_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2026102711130452600_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"2026102711130452600_bib41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41594-023-01188-0","article-title":"Structural insights into branch site proofreading by human spliceosome","volume":"31","author":"Zhang","year":"2024","journal-title":"Nat Struct Mol Biol"},{"issue":"23","key":"2026102711130452600_bib42","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1182\/blood-2013-02-427641","article-title":"SF3B1 mutations in chronic lymphocytic leukemia","volume":"121","author":"Wan","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2026102711130452600_bib43","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/cncr.33745","article-title":"Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes","volume":"127","author":"Kanagal-Shamanna","year":"2021","journal-title":"Cancer"},{"key":"2026102711130452600_bib44","doi-asserted-by":"crossref","first-page":"905490","DOI":"10.3389\/fonc.2022.905490","article-title":"A novel prognostic scoring model for myelodysplastic syndrome patients with SF3B1 mutation","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"issue":"24","key":"2026102711130452600_bib45","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.3390\/ijms21249546","article-title":"Spliceosome mutations in uveal melanoma","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026102711130452600_bib46","doi-asserted-by":"crossref","first-page":"e138315","DOI":"10.1172\/JCI138315","article-title":"Mutant SF3B1 promotes AKT- and NF-\u03baB-driven mammary tumorigenesis","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"issue":"20","key":"2026102711130452600_bib47","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-18-3965","article-title":"SF3B2-mediated RNA splicing drives human prostate cancer progression","volume":"79","author":"Kawamura","year":"2019","journal-title":"Cancer Res"},{"issue":"2","key":"2026102711130452600_bib48","doi-asserted-by":"crossref","first-page":"e63886","DOI":"10.1002\/ajmg.a.63886","article-title":"SF3B2 haploinsufficiency associated with Hirschsprung disease and complex cardiac defect without craniofacial microsomia","volume":"197","author":"Del Viso","year":"2025","journal-title":"Am J Med Genet A"},{"issue":"5s","key":"2026102711130452600_bib49","doi-asserted-by":"crossref","first-page":"102486","DOI":"10.1016\/j.jormas.2025.102486","article-title":"Haploinsufficiency of SF3B2 revealed by a craniofacial microsomia with atypical presentation: a case report","volume":"126","author":"Octau","year":"2025","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"10","key":"2026102711130452600_bib50","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/00220345251325818","article-title":"Splicing defects and cell death cause SF3B2-linked craniofacial microsomia","volume":"104","author":"Rao","year":"2025","journal-title":"J Dent Res"},{"issue":"4","key":"2026102711130452600_bib51","doi-asserted-by":"crossref","first-page":"167115","DOI":"10.1016\/j.bbadis.2024.167115","article-title":"Identification of splicing factors signature predicting prognosis risk and the mechanistic roles of novel oncogenes in HNSCC","volume":"1870","author":"Chen","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026102711130452600_bib52","doi-asserted-by":"crossref","first-page":"118281","DOI":"10.1016\/j.ecoenv.2025.118281","article-title":"Multidimensional bioinformatics analysis reveals the potential carcinogenic role of acrylamide in colorectal cancer","volume":"298","author":"Yu","year":"2025","journal-title":"Ecotoxicol Environ Saf"},{"issue":"Pt 3","key":"2026102711130452600_bib53","doi-asserted-by":"crossref","first-page":"135692","DOI":"10.1016\/j.ijbiomac.2024.135692","article-title":"Fgf8 contributes to the pathogenesis of Nager syndrome","volume":"280","author":"Ulhaq","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"2026102711130452600_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5483\/BMBRep.2018.51.2.021","article-title":"SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma","volume":"51","author":"Shen","year":"2018","journal-title":"BMB Rep"},{"issue":"1","key":"2026102711130452600_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41419-022-05534-w","article-title":"SF3B4 promotes Twist1 expression and clear cell renal cell carcinoma progression by facilitating the export of KLF 16 mRNA from the nucleus to the cytoplasm","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"1","key":"2026102711130452600_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s10020-021-00347-7","article-title":"The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC","volume":"27","author":"Li","year":"2021","journal-title":"Mol Med"},{"issue":"1","key":"2026102711130452600_bib57","doi-asserted-by":"crossref","first-page":"39840","DOI":"10.1038\/s41598-025-23477-y","article-title":"SF3B6 promotes the oncogenic phenotypes of MDA-MB-231 cells by extensively interacting with and regulating transcripts expression and alternative splicing","volume":"15","author":"Yuan","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"2026102711130452600_bib58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/1878-0261.12052","article-title":"A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment","volume":"11","author":"Siebring-van Olst","year":"2017","journal-title":"Mol Oncol"},{"issue":"5","key":"2026102711130452600_bib59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-associated SF3B1 hotspot mutations induce cryptic 3' splice site selection through use of a different branch point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep"},{"issue":"17","key":"2026102711130452600_bib60","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/0008-5472.CAN-20-4016","article-title":"Nonsense-mediated RNA decay is a unique vulnerability of cancer cells harboring SF3B1 or U2AF1 mutations","volume":"81","author":"Cheruiyot","year":"2021","journal-title":"Cancer Res"},{"key":"2026102711130452600_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2021.01.084","article-title":"Characterization of the aberrant splicing of DVL2 induced by cancer-associated SF3B1 mutation","volume":"546","author":"Zhao","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2026102711130452600_bib62","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3324\/haematol.2020.261891","article-title":"SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation","volume":"106","author":"Pozzo","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2026102711130452600_bib63","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.3390\/cancers14122997","article-title":"Multiple mechanisms of NOTCH1 activation in chronic lymphocytic leukemia: NOTCH1 mutations and beyond","volume":"14","author":"Pozzo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026102711130452600_bib64","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1158\/0008-5472.CAN-06-0974","article-title":"Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1","volume":"66","author":"Stahl","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"2026102711130452600_bib65","doi-asserted-by":"crossref","first-page":"e2111703119","DOI":"10.1073\/pnas.2111703119","article-title":"SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes","volume":"119","author":"Lieu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102711130452600_bib66","doi-asserted-by":"crossref","first-page":"78136","DOI":"10.7554\/eLife.78136","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations","volume":"11","author":"Choudhary","year":"2022","journal-title":"Elife"},{"key":"2026102711130452600_bib67","doi-asserted-by":"crossref","first-page":"101055","DOI":"10.1016\/j.jbior.2024.101055","article-title":"Hyperactivation of NF-\u03baB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches","volume":"95","author":"Pellagatti","year":"2025","journal-title":"Adv Biol Regul"},{"issue":"6","key":"2026102711130452600_bib68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/2159-8290.CD-20-0358","article-title":"Splice of life for cancer: missplicing of PPP2R5A by mutant SF3B1 leads to MYC stabilization and tumorigenesis","volume":"10","author":"O'Connor","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"2026102711130452600_bib69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/cancers14020281","article-title":"Recurrent spliceosome mutations in cancer: mechanisms and consequences of aberrant splice site selection","volume":"14","author":"Ni\u00f1o","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2026102711130452600_bib70","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/s41375-024-02379-4","article-title":"The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia","volume":"38","author":"H\u00e4gerstrand","year":"2024","journal-title":"Leukemia"},{"issue":"500","key":"2026102711130452600_bib71","doi-asserted-by":"crossref","first-page":"eaav5467","DOI":"10.1126\/scitranslmed.aav5467","article-title":"A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome","volume":"11","author":"Bondu","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026102711130452600_bib72","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1038\/s41598-022-18921-2","article-title":"Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome","volume":"12","author":"Ochi","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"2026102711130452600_bib73","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/leu.2016.149","article-title":"Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes","volume":"30","author":"Dolatshad","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2026102711130452600_bib74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.26090","article-title":"Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u201c2021 update on diagnosis, risk-stratification, and management\u201d","volume":"96","author":"Patnaik","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2026102711130452600_bib75","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1172\/JCI125022","article-title":"Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation","volume":"129","author":"Dalton","year":"2019","journal-title":"J Clin Invest"},{"issue":"18","key":"2026102711130452600_bib76","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","article-title":"Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes","volume":"78","author":"Nguyen","year":"2018","journal-title":"Cancer Res"},{"issue":"11","key":"2026102711130452600_bib77","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3324\/haematol.2020.254193","article-title":"Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations","volume":"106","author":"Flach","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2026102711130452600_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/0008-5472.CAN-23-3239","article-title":"R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res"},{"issue":"8","key":"2026102711130452600_bib79","doi-asserted-by":"crossref","first-page":"111266","DOI":"10.1016\/j.celrep.2022.111266","article-title":"SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer","volume":"40","author":"Simmler","year":"2022","journal-title":"Cell Rep"},{"issue":"11","key":"2026102711130452600_bib80","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026102711130452600_bib81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-024-03053-4","article-title":"SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis","volume":"43","author":"Xu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2026102711130452600_bib82","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41419-022-04630-1","article-title":"SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52","volume":"13","author":"Diao","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026102711130452600_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ebiom.2018.10.067","article-title":"SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma","volume":"38","author":"Liu","year":"2018","journal-title":"EBioMedicine"},{"issue":"19","key":"2026102711130452600_bib84","doi-asserted-by":"crossref","first-page":"eadr3173","DOI":"10.1126\/sciadv.adr3173","article-title":"Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m(6)A modification in triple-negative breast cancer","volume":"11","author":"Yu","year":"2025","journal-title":"Sci Adv"},{"issue":"21-24","key":"2026102711130452600_bib85","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.351154.123","article-title":"Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing","volume":"37","author":"Zhang","year":"2023","journal-title":"Genes Dev"},{"issue":"4","key":"2026102711130452600_bib86","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41556-023-01109-9","article-title":"DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells","volume":"25","author":"Ramabadran","year":"2023","journal-title":"Nat Cell Biol"},{"issue":"pt 6","key":"2026102711130452600_bib87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1107\/S2053230X17007336","article-title":"The crystal structure of human DEAH-box RNA helicase 15 reveals a domain organization of the mammalian DEAH\/RHA family","volume":"73","author":"Murakami","year":"2017","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"issue":"49","key":"2026102711130452600_bib88","doi-asserted-by":"crossref","first-page":"e2216712119","DOI":"10.1073\/pnas.2216712119","article-title":"DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2026102711130452600_bib89","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.molcel.2024.04.006","article-title":"GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies","volume":"84","author":"Benbarche","year":"2024","journal-title":"Mol Cell"},{"issue":"8","key":"2026102711130452600_bib90","doi-asserted-by":"crossref","first-page":"116075","DOI":"10.1016\/j.celrep.2025.116075","article-title":"SUGP1 loss drives SF3B1 hotspot mutant missplicing in cancer","volume":"44","author":"Xing","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"2026102711130452600_bib91","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41467-023-36489-x","article-title":"Mechanisms of the RNA helicases DDX42 and DDX46 in human U2 snRNP assembly","volume":"14","author":"Yang","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"2026102711130452600_bib92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jb\/mvac049","article-title":"Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42","volume":"172","author":"Zhao","year":"2022","journal-title":"J Biochem"},{"issue":"2","key":"2026102711130452600_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/gtc.12824","article-title":"G-quadruplex-forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression","volume":"26","author":"Matsumoto","year":"2021","journal-title":"Genes Cells"},{"issue":"3","key":"2026102711130452600_bib94","doi-asserted-by":"crossref","first-page":"001376","DOI":"10.1099\/jgv.0.001376","article-title":"Nuclear localization of Zika virus NS5 contributes to suppression of type I interferon production and response","volume":"102","author":"Zhao","year":"2021","journal-title":"J Gen Virol"},{"issue":"2","key":"2026102711130452600_bib95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.virs.2022.12.005","article-title":"Splicing factor SF3B3, a NS5-binding protein, restricts ZIKV infection by targeting GCH1","volume":"38","author":"Chen","year":"2023","journal-title":"Virol Sin"},{"key":"2026102711130452600_bib96","doi-asserted-by":"crossref","first-page":"217530","DOI":"10.1016\/j.canlet.2025.217530","article-title":"Splicing factor SF3B4 acts as a switch in cancer cell senescence by regulating p21 mRNA stability","volume":"615","author":"Kang","year":"2025","journal-title":"Cancer Lett"},{"issue":"6","key":"2026102711130452600_bib97","doi-asserted-by":"crossref","first-page":"622","DOI":"10.21873\/cgp.20478","article-title":"SF3B4 regulates cellular senescence and suppresses therapy-induced senescence of cancer cells","volume":"21","author":"Yang","year":"2024","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"2026102711130452600_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1381","article-title":"Modulating splicing with small molecular inhibitors of the spliceosome","volume":"8","author":"Effenberger","year":"2017","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"3-4","key":"2026102711130452600_bib99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1101\/gad.311043.117","article-title":"The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action","volume":"32","author":"Finci","year":"2018","journal-title":"Genes Dev"},{"issue":"1","key":"2026102711130452600_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2025.2470511","article-title":"RNA-binding proteins as therapeutic targets in cancer","volume":"22","author":"Jungfleisch","year":"2025","journal-title":"RNA Biol"},{"issue":"9","key":"2026102711130452600_bib101","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1242\/jcs.202200","article-title":"Pharmacological inhibition of the spliceosome subunit SF3b triggers exon junction complex-independent nonsense-mediated decay","volume":"130","author":"Carvalho","year":"2017","journal-title":"J Cell Sci"},{"issue":"1","key":"2026102711130452600_bib102","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1038\/s41467-021-24741-1","article-title":"Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors","volume":"12","author":"Cretu","year":"2021","journal-title":"Nat Commun"},{"key":"2026102711130452600_bib103","doi-asserted-by":"crossref","first-page":"15522","DOI":"10.1038\/ncomms15522","article-title":"Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex","volume":"8","author":"Teng","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"2026102711130452600_bib104","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molcel.2018.03.011","article-title":"Structural basis of splicing modulation by antitumor macrolide compounds","volume":"70","author":"Cretu","year":"2018","journal-title":"Mol Cell"},{"issue":"3","key":"2026102711130452600_bib105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1261\/rna.053108.115","article-title":"Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages","volume":"22","author":"Effenberger","year":"2016","journal-title":"Rna"},{"issue":"4","key":"2026102711130452600_bib106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"2026102711130452600_bib107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/iovs.65.12.11","article-title":"The impact of spliceosome inhibition in SF3B1-mutated uveal melanoma","volume":"65","author":"Nguyen","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"2026102711130452600_bib108","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.7150\/ijbs.92671","article-title":"Exploring splicing modulation as an innovative approach to combat pancreatic cancer: SF3B1 emerges as a prognostic indicator and therapeutic target","volume":"20","author":"Sciarrillo","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"9","key":"2026102711130452600_bib109","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/00498254.2019.1709134","article-title":"Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans","volume":"50","author":"Rioux","year":"2020","journal-title":"Xenobiotica"},{"issue":"728","key":"2026102711130452600_bib110","doi-asserted-by":"crossref","first-page":"eade2774","DOI":"10.1126\/scitranslmed.ade2774","article-title":"Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML","volume":"16","author":"Wheeler","year":"2024","journal-title":"Sci Transl Med"},{"issue":"2","key":"2026102711130452600_bib111","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2020.12.031","article-title":"Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer","volume":"184","author":"Bowling","year":"2021","journal-title":"Cell"},{"issue":"3","key":"2026102711130452600_bib112","doi-asserted-by":"crossref","first-page":"eabj8357","DOI":"10.1126\/sciadv.abj8357","article-title":"SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia","volume":"8","author":"Han","year":"2022","journal-title":"Sci Adv"},{"issue":"11","key":"2026102711130452600_bib113","doi-asserted-by":"crossref","first-page":"e202301955","DOI":"10.26508\/lsa.202301955","article-title":"SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia","volume":"6","author":"L\u00f3pez-Oreja","year":"2023","journal-title":"Life Sci Alliance"},{"key":"2026102711130452600_bib114","doi-asserted-by":"crossref","first-page":"107735","DOI":"10.1016\/j.leukres.2025.107735","article-title":"Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B-8800 in lower-risk myelodysplastic syndrome","volume":"156","author":"Foran","year":"2025","journal-title":"Leuk Res"},{"issue":"12","key":"2026102711130452600_bib115","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2026102711130452600_bib116","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/nar\/gku151","article-title":"Sudemycin E influences alternative splicing and changes chromatin modifications","volume":"42","author":"Convertini","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026102711130452600_bib117","doi-asserted-by":"crossref","first-page":"129739","DOI":"10.1016\/j.bmcl.2024.129739","article-title":"Synthesis and antiproliferative activity of a tetrahydrofuran analog of FR901464","volume":"104","author":"Pohorilets","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"2026102711130452600_bib118","doi-asserted-by":"crossref","first-page":"e13198","DOI":"10.1111\/pcmr.13198","article-title":"Pathogenic germline variants in uveal melanoma driver and BAP1-associated genes in finnish patients with uveal melanoma","volume":"38","author":"Repo","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"2026102711130452600_bib119","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/acschembio.0c00965","article-title":"Herboxidiene features that mediate conformation-dependent SF3B1 interactions to inhibit splicing","volume":"16","author":"Gamboa Lopez","year":"2021","journal-title":"ACS Chem Biol"},{"issue":"6","key":"2026102711130452600_bib120","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1039\/D0OB02532A","article-title":"Design and synthesis of herboxidiene derivatives that potently inhibit in vitro splicing","volume":"19","author":"Ghosh","year":"2021","journal-title":"Org Biomol Chem"},{"key":"2026102711130452600_bib121","doi-asserted-by":"crossref","first-page":"100776","DOI":"10.1016\/j.jbior.2020.100776","article-title":"SF3B1 mutant myelodysplastic syndrome: recent advances","volume":"79","author":"Pellagatti","year":"2021","journal-title":"Adv Biol Regul"},{"key":"2026102711130452600_bib122","doi-asserted-by":"crossref","first-page":"1116438","DOI":"10.3389\/fonc.2023.1116438","article-title":"SF3B1 mutations in myelodysplastic syndromes: a potential therapeutic target for modulating the entire disease process","volume":"13","author":"Jiang","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"2026102711130452600_bib123","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/hem3.70103","article-title":"Low-risk MDS-A spotlight on precision medicine for SF3B1-mutated patients","volume":"9","author":"Burke","year":"2025","journal-title":"Hemasphere"},{"issue":"1","key":"2026102711130452600_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026102711130452600_bib125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41375-025-02831-z","article-title":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat","volume":"40","author":"Santini","year":"2026","journal-title":"Leukemia"},{"issue":"10423","key":"2026102711130452600_bib126","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"2026102711130452600_bib127","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2026102711130452600_bib128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2643-3230.BCD-21-0220","article-title":"Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts","volume":"3","author":"Adema","year":"2022","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6915\/2595097\/blooda_adv-2026-020106-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/6915\/2595097\/blooda_adv-2026-020106-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:13:22Z","timestamp":1793114002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/6915\/570168\/The-SF3b-complex-in-cancer-structural-basis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":128,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020106","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,14]]}}}